Search Results

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, announced recent business progress and second quarter 2021 financial results.

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, announced that members of its senior management team will participate in three upcoming virtual investor conferences.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it intends to offer for sale shares of its common stock and, to a certain investor in lieu thereof, pre-funded warrants to purchase shares of common stock